J&J decides against Erleada+Zytiga combination prostate cancer filingJohnson & Johnson won’t be filing a prostate cancer therapy combining its Erleada and Zytiga drugs with regulators, Share XJ&J decides against Erleada+Zytiga combination prostate cancer filinghttps://pharmaphorum.com/news/jj-decides-against-erleadazytiga-combination-prostate-cancer-filing/
Novartis’ radioligand therapy meets phase 3 prostate cancer trial targetNovartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist Share XNovartis’ radioligand therapy meets phase 3 prostate cancer trial targethttps://pharmaphorum.com/news/novartis-radioligand-therapy-meets-target-in-prostate-cacner/
NICE says no to AZ’s Lynparza for prostate cancerNHS patients in England will not be able to get access to AstraZeneca’s PARP inhibitor Lynparza if they Share XNICE says no to AZ’s Lynparza for prostate cancerhttps://pharmaphorum.com/news/nice-says-no-to-azs-lynparza-for-prostate-cancer/
Sharing experiences to level the healthcare playing fieldAmanda Barrell speaks to Alfred Samuels on his experience of prostate cancer and diversifying clinical trials to include Share XSharing experiences to level the healthcare playing fieldhttps://pharmaphorum.com/views-analysis-oncology/sharing-experiences-to-level-the-healthcare-playing-field/
Valirx eyes partnerships as first VAL201 study hits the markShares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of Share XValirx eyes partnerships as first VAL201 study hits the markhttps://pharmaphorum.com/news/valirx-eyes-partnerships-as-first-val201-study-hits-the-mark/
EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancerAstraZeneca may have had a rough ride following a safety scare with its COVID-19 vaccine, but the company’s Share XEU regulators back uses for AZ’s Lynparza in prostate and ovarian cancerhttps://pharmaphorum.com/news/az-grabs-twin-eu-approval-for-lynparza-in-prostate-and-ovarian-cancer-uses/
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&DCalifornia biotech Poseida Therapeutics has become the latest biotech to hit the IPO trial after a string of launches last Share XPoseida Therapeutics aims for $115m stock market launch to fund CAR-T R&Dhttps://pharmaphorum.com/news/poseida-therapeutics/
Mixed results for Roche drugs in prostate cancer and COVID-19Two eye-catching research projects involving drugs from Roche have produced disappointing trial results, after its prostate cancer drug Share XMixed results for Roche drugs in prostate cancer and COVID-19https://pharmaphorum.com/news/mixed-results-for-roche-drugs-in-prostate-cancer-and-covid-19/
AZ/Merck & Co take on Clovis as FDA approves prostate cancer drugThe FDA has approved AstraZeneca and Merck & Co’s Lynparza (olaparib) in metastatic castration-resistant prostate cancer, just days after the regulator Share XAZ/Merck & Co take on Clovis as FDA approves prostate cancer drughttps://pharmaphorum.com/news/az-merck-cos-lynparza/
